Loading company…
Rinascera Therapeutics develops therapies for rare genetic skin diseases, including Gorlin Syndrome and Dystrophic Epidermolysis Bullosa.
Rinascera Therapeutics is developing RIN-001, a topical kinase inhibitor for Gorlin Syndrome and frequent sporadic basal cell carcinomas, and RIN-002, an intravenous collagen VII replacement therapy for Dystrophic Epidermolysis Bullosa. The company was founded in 2025 in Boston, US, and co-founded by Nichola Eliovits. On 16 July 2026, it secured undisclosed initial financing led by Double Point Ventures, with Olive Tree Capital, Civilization Ventures, and Toba Capital participating.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in